Nanobiotix regains the €26 level but falls 12.5% over the week

A 3.68% rebound that brings the stock back above its MM20

Nanobiotix gains 3.68% to €26.48, while the CAC 40 rises 1.5% and the SBF 120 rises 1.47%.

The stock is among the strongest gainers in the SBF 120, but it remains down over the week, at -12.61%. This rebound places it 10.06% above its MM20 (€24.06), while it remains 4.44% below its MM50 (€27.71).

Over one month, the stock still shows a gain of +15.84%, which contrasts with the decline of nearly 22% over three months. The stock is thus approaching its MM50, while resistance at €30.36 remains further away.

Above the MM20, short-term momentum is improving, although the medium-term trend has not been reversed: the price remains 9.90% below the MM200.

A single company listed in Paris and on the Nasdaq, with cash reported to fund operations until 2029

Nanobiotix is a single company listed on two exchanges: the ordinary share in Paris, eligible for the PEA, and the ADS on the Nasdaq, at a ratio of one to one. Both lines mostly move on the same day, and Nasdaq movements after the Paris close partly carry over to the next day's opening.

As a reminder, when it published its H1 2026 results on September 24, the company reported cash of €110.9 million, enough to fund its operations until 2029. This reminder puts into context the financial backdrop of a stock that had rebounded sharply at the end of October, with a gain of +46.5% in one week according to our October 28 brief, before retreating.

The support level at €18.85 is the lowest of the technical reference points, and the resistance level at €30.36 is the highest.